Natera (NASDAQ:NTRA) Price Target Raised to $190.00

Natera (NASDAQ:NTRA) had its price objective lifted by Wells Fargo & Company from $175.00 to $190.00 in a research report report published on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical research company’s stock.

Other analysts have also issued research reports about the stock. Barclays raised their price target on shares of Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a report on Friday. BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price for the company in a research note on Monday, October 27th. Cowen restated a “buy” rating on shares of Natera in a research report on Friday, August 8th. BTIG Research raised their price target on Natera from $210.00 to $230.00 and gave the company a “buy” rating in a report on Friday. Finally, BNP Paribas upgraded Natera to a “hold” rating and set a $172.00 price objective for the company in a research report on Monday, October 27th. Seventeen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $206.74.

Natera Price Performance

Shares of NTRA traded up $7.06 on Friday, hitting $206.63. The company’s stock had a trading volume of 1,452,469 shares, compared to its average volume of 1,426,470. The company has a market capitalization of $28.36 billion, a PE ratio of -90.23 and a beta of 1.74. Natera has a fifty-two week low of $125.38 and a fifty-two week high of $210.90. The company has a 50 day moving average price of $177.75 and a 200 day moving average price of $163.91.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, November 6th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.20% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same period in the prior year, the firm posted ($0.26) EPS. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Natera will post -1.49 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Steven Leonard Chapman sold 160,703 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the sale, the chief executive officer owned 144,816 shares of the company’s stock, valued at $28,957,407.36. This trade represents a 52.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John Fesko sold 928 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $191.46, for a total transaction of $177,674.88. Following the sale, the insider owned 150,699 shares in the company, valued at $28,852,830.54. This trade represents a 0.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 224,889 shares of company stock worth $43,232,062. 5.63% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Bank of Jackson Hole Trust bought a new position in shares of Natera during the 1st quarter worth approximately $29,000. Hilltop National Bank acquired a new position in shares of Natera during the 2nd quarter worth about $33,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Natera in the 2nd quarter valued at about $36,000. Sound Income Strategies LLC increased its position in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the last quarter. Finally, TCTC Holdings LLC raised its holdings in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.